

Understanding Brain Inflammation in Cognitive Problems (BRIC)

Submission date 28/03/2024	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 09/07/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 19/05/2025	Condition category Nervous System Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Dementia with Lewy bodies (DLB) affects one hundred thousand people in the UK. The causes of DLB are not completely understood but it is expected that the immune system plays an important role, as it does with Alzheimer's disease (AD). In AD, activation of the immune system is thought to happen years before the symptoms of dementia occur. This immune activation increases the risk of developing AD in later life. Also, events that activate the immune system in the blood, such as urine infections, are known to cause worsening of memory symptoms in people who already have AD. We do not yet know if the same is true in DLB.

We will measure inflammation in the body using blood tests to answer important questions such as:

1. Are cognitive problems associated with inflammation?
2. Is inflammation associated with the progression of cognitive problems?

Who can participate?

People aged 60 years and over with specific cognitive problems, along with people aged 60 years and over without cognitive problems.

What does the study involve?

All participants will have a clinical assessment and blood samples. The clinical assessment will help the researchers to understand the problems people are experiencing, and if their problems are progressing over time. Blood samples will show how inflammation in the body affects the brain. Participants will have a further clinical assessment and blood samples annually for 2 years. The findings of this study could identify inflammation as a new treatment target for people with cognitive problems.

What are the possible benefits and risks of participating?

There is no direct benefit from taking part in this study. However, the information from this study may help improve the future treatment of people with cognitive problems.

Where is the study run from?

University of Southampton (UK)

When is the study starting and how long is it expected to run for?
February 2020 to September 2029

Who is funding the study?
Lewy Body Society (UK)

Who is the main contact?
Dr Jay Amin, jay.amin@soton.ac.uk

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Dr Jay Amin

ORCID ID

<http://orcid.org/0000-0003-3792-0428>

Contact details

Memory Assessment and Research Centre (MARC), Tom Rudd Unit, Moorgreen Hospital, Botley Road
Southampton
United Kingdom
SO30 3JB
+44 (0)2380475206
jay.amin@soton.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

305370

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 54263

Study information

Scientific Title

Understanding Brain Inflammation in Cognitive Problems (BRIC)

Acronym

BRIC

Study objectives

Current Study hypothesis as of 16/05/2025:

1. MCI-LB/mild DLB will show an increased peripheral pro-inflammatory profile and increased immunosenescent profile at baseline compared to controls.
2. Increased immunosenescent markers at baseline will be associated with more rapid disease progression in MCI-LB/mild DLB.
3. More frequent occurrence of peripheral pro-inflammatory events (e.g. infections, surgery) will be associated with increased pro-inflammatory cytokines and more rapid disease progression in MCI-LB/mild DLB.

Previous Study hypothesis:

1. Mild cognitive impairment with Lewy bodies (MCI-LB)/mild dementia with Lewy bodies (DLB) will be associated with increased 18F-DPA714 binding, which will be associated with more rapid disease progression.
2. 18F-DPA714 binding will decline over time in MCI-LB/mild DLB.
3. MCI-LB/mild DLB will show an altered peripheral inflammatory profile at baseline compared to controls.
4. Alterations in immunosenescent markers at baseline will be associated with more rapid disease progression in MCI-LB/mild DLB.
5. More frequent occurrence of peripheral pro-inflammatory events (e.g. infections, surgery) will be associated with increased pro-inflammatory cytokines and more rapid disease progression in MCI-LB/mild DLB.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 15/11/2022, Wales REC 7 (St David's Park, Carmarthen, SA31 3HB, United Kingdom; +44 (0)2922 941107; Wales.REC7@wales.nhs.uk), ref: 22/WA/0312

Study design

Longitudinal observational case-control study

Primary study design

Observational

Secondary study design

Case-control study

Study setting(s)

Hospital, University/medical school/dental school

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Dementia with Lewy bodies

Interventions

Current interventions as of 16/05/2025:

At the initial baseline assessment, consent and clinical assessment will be carried out over two visits, each taking 1-2 hours. This will include a blood test.

Follow-up will take place annually for 2 years. After 1 year, the researchers will contact study volunteers to see if they are happy to have an appointment to repeat some of the assessments, have a blood sample and repeat the questionnaires with a relative/friend, taking 1-2 hours.

After 2 years, the researchers will contact study volunteers to see if they are happy to have clinical assessment, questionnaires and a repeat blood sample, taking 1-2 hours.

Previous interventions:

At the initial baseline assessment, consent and clinical assessment will be carried out over two visits, each taking 1-2 hours. This will include a blood test. Most participants will have brain scans (a combined PET and MRI scan, or separate PET and MRI scans on different days, each taking 1-1.5 hours).

Follow-up will take place annually for 2 years. After 1 year, the researchers will contact study volunteers to see if they are happy to have an appointment to repeat some of the assessments, have a blood sample and repeat the questionnaires with a relative/friend, taking 1-2 hours.

After 2 years, the researchers will contact study volunteers to see if they are happy to have repeat brain imaging, clinical assessment, questionnaires and a repeat blood sample, taking 1-2 hours.

Intervention Type

Other

Primary outcome measure

Current primary outcome measure as of 16/05/2025:

Peripheral blood inflammatory profile is measured by flow cytometry of cells and analysis of inflammatory markers at baseline, 1 year and 2 years.

Previous primary outcome measure:

Brain Mitochondrial Translocator Protein (TSPO) is measured by 18F-DPA714 binding (mean cortical and regional) at baseline and 2 years

Secondary outcome measures

Current secondary outcome measures as of 16/05/2025:

1. Cognition is measured using the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) at baseline, 1 year and 2 years.
2. Global functional impairment is measured using the Clinical Dementia Rating Scale Sum of Boxes at baseline, 1 year and 2 years.

Previous secondary outcome measures:

1. Peripheral blood inflammatory profile is measured by flow cytometry of cells and analysis of inflammatory markers at baseline, 1 year and 2 years
2. Cognition is measured using the Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) at baseline, 1 year and 2 years
3. Global functional impairment is measured using the Clinical Dementia Rating Scale Sum of Boxes at baseline, 1 year and 2 years

Overall study start date

01/02/2020

Completion date

01/09/2029

Eligibility

Key inclusion criteria

MCI-LB/DLB group:

1. Age ≥ 60 years
2. Fulfil criteria for probable MCI-LB (McKeith et al., 2020) or DLB (McKeith et al., 2017)
3. Capacity to consent to participation in the study
4. MMSE ≥ 20
5. If on cholinesterase inhibitors and/or memantine, stable dose for 3 months

Control group:

1. Age ≥ 60 years
2. MMSE ≥ 27
3. No evidence of mild cognitive impairment or dementia

Participant type(s)

Healthy volunteer, Patient

Age group

Adult

Lower age limit

60 Years

Upper age limit

120 Years

Sex

Both

Target number of participants

70

Key exclusion criteria

1. Active systemic inflammatory disease
2. Active autoimmune disease
3. Taking immune system modifying medications (e.g., oral steroids or tumour necrosis factor inhibitors)
4. Taking incretin analogues (e.g., liraglutide), minocycline or other microglial suppressing agents
5. History of clinical stroke
6. Current major depression
7. History of bipolar disorder, non-organic psychosis (e.g., longstanding schizophrenia) or recurrent severe depression
8. Chronic migraine

Date of first enrolment

14/02/2024

Date of final enrolment

14/08/2027

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Hampshire and Isle of Wight Healthcare NHS Foundation Trust

Tatchbury Mount Hospital

Calmore

Southampton

United Kingdom

SO40 2RZ

Sponsor information

Organisation

University of Southampton

Sponsor details

University Road
Southampton
England
United Kingdom
SO17 1BJ
+44 2380 595058
rgoinfo@soton.ac.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.southampton.ac.uk/>

ROR

<https://ror.org/01ryk1543>

Funder(s)**Funder type**

Charity

Funder Name

Lewy Body Society

Alternative Name(s)

The Lewy body Society, LBS

Funding Body Type

Government organisation

Funding Body Subtype

Associations and societies (private and public)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The results from this research will be shared with the wider research community through publication in high-impact journals in the fields of clinical medicine and medical imaging, and presentation at international conferences. The researchers will seek to disseminate their findings to the public through local, regional and/or international meetings.

Intention to publish date

01/03/2028

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a non-publicly available repository (<https://www.dementiasplatform.uk/>)

IPD sharing plan summary

Stored in non-publicly available repository